Assembly Biosciences (STU:V7B) FCF Yield %: -7.20 (As of Jul. 10, 2026)


STU:V7B Assembly Biosciences Inc STU:V7B
31 GF Score
Price €24.00
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences FCF Yield %?

Assembly Biosciences STU:V7B -4.14% 31 FCF Yield % is -7.20 as of Jul. 10, 2026. GuruFocus rates STU:V7B with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,408 Biotechnology companies, Assembly Biosciences ranks better than 55.33% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Assembly Biosciences's Trailing 12-Month Free Cash Flow is €-34.39 Mil, and Market Cap is €484.99 Mil. Therefore, Assembly Biosciences's FCF Yield % for today is -7.20%.

The historical rank and industry rank for Assembly Biosciences's FCF Yield % or its related term are showing as below:

STU:V7B' s FCF Yield % Range Over the Past 10 Years
Min: -243.59   Med: -17.57   Max: 44.07
Current: -7.2


During the past 13 years, the highest FCF Yield % of Assembly Biosciences was 44.07%. The lowest was -243.59%. And the median was -17.57%.

STU:V7B's FCF Yield % is ranked better than
55.33% of 1408 companies
in the Biotechnology industry
Industry Median: -9.41 vs STU:V7B: -7.20

Assembly Biosciences's FCF Margin % for the quarter that ended in Mar. 2026 was -269.28%.


Assembly Biosciences FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Assembly Biosciences FCF Yield % Related Terms


Assembly Biosciences FCF Yield % Historical Data

* Premium members only.

The historical data trend for Assembly Biosciences's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences FCF Yield % Chart

Assembly Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -92.91 -138.00 41.57 -46.95 -8.15

Assembly Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -126.75 -50.17 -16.22 11.28 -20.32

STU:V7B vs CTNM, PRTA, RGNX: FCF Yield % Comparison

For the Biotechnology subindustry, Assembly Biosciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's FCF Yield % falls into.


STU:V7B
31GF Score
Assembly Biosciences Inc STU:V7B
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Assembly Biosciences's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-35.149 / 431.256
=-8.15%

Assembly Biosciences's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-19.13 * 4 / 376.6404
=-20.32%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -7.20 mean?
Assembly Biosciences (STU:V7B) has a FCF Yield % of -7.20 as of Jul. 10, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Assembly Biosciences and its competitors. According to the industry distribution chart, Assembly Biosciences ranks #629 out of 1408 companies in the Biotechnology industry, placing it in the top 44.7%.
Is Assembly Biosciences' FCF Yield % too high?
Assembly Biosciences' current FCF Yield % is -7.20. Based on the distribution chart, Assembly Biosciences ranks #629 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Assembly Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' FCF Yield % compare to CTNM and PRTA?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #629 out of 1408 companies for FCF Yield %. This puts Assembly Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current FCF Yield % is -7.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (STU:V7B) has a current FCF Yield % of -7.20. The current FCF Yield % is -7.20. Assembly Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Assembly Biosciences (STU:V7B), the current FCF Yield % is -7.20 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Assembly Biosciences Business Description

Other Exchanges ASMB:USA
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score

Get the complete analysis for STU:V7B

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.00
Price